Nature Reviews Cancer contents November 2012 Volume 12 Number 11 pp 733-792

Advertisement
Thousands of reporter vectors at your fingertips! The LightSwitch Luciferase Reporter Assay System provides everything you need to study gene regulation in living cells: 18,000 pre-cloned human promoters and 12,000 3'UTRs in luciferase reporter vectors, synthetic elements, and optimized reagents. Measure promoter induction or validate miRNA targets using the pre-cloned reporter collection or use the new custom cloning and mutagenesis services. Visit SwitchGear Genomics to learn more.
TABLE OF CONTENTS
November 2012 Volume 12 Number 11		Advertisement
Impact Factor 37.545 *	In this issue Research Highlights Reviews Perspectives Also this month  Featured article: The NAD metabolome – a key determinant of cancer cell biology Alberto Chiarugi, Christian Dölle, Roberta Felici & Mathias Ziegler	Get the most from your NGS data with Sequenom’s MassARRAY® system • Validate from tens to thousands of samples across tens to hundreds of SNPs • Design you own assays against any SNP of interest • Run a variety of applications including genotyping, DNA methylation and somatic mutation analysis
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Discover the tumour models designed to be truly representative of clinical outcomes Tumour Models (29-31 Jan 2013, London) is the only meeting in Europe to focus on: optimising traditional models exploring practical alternatives and better predicting drug efficacy Featuring experts from companies at the forefront of tumour model technology showcasing their approaches.
Advertisement
Nature and Nature Reviews Cancer COLLECTION ON CANCER METABOLISM This joint Collection from Nature and Nature Reviews Cancer highlights recent progress in the field and the promise of therapeutics based on interfering with metabolic pathways. Access the Web Focus at: www.nature.com/focus/cancermetabolism Papers in the reprint collection are freely available thanks to sponsorship from Teva Pharmaceuticals
RESEARCH HIGHLIGHTS Top Tumorigenesis: Megaphone MYC p733 | doi:10.1038/nrc3384 Is the transcription factor MYC an amplifier of gene transcription? PDF DNA damage: The enemy within p734 | doi:10.1038/nrc3381 Reactive aldehydes generated by metabolism may contribute to the pathogenesis of Fanconi anaemia. PDF Tumorigenesis: Influencing those around you p734 | doi:10.1038/nrc3385 Mitochondrial defects in cells expressing oncogenic RASV12 can induce surrounding cells to proliferate owing to effects on the Hippo pathway. PDF IN THE NEWS Fatal attraction p735 | doi:10.1038/nrc3389 New research suggests that magnetic nanoparticles could be used to induce apoptosis in cancer cells. PDF Angiogenesis: A deeper understanding of VEGFR inhibitors p735 | doi:10.1038/nrc3390 An analysis of the structual binding and potency of vascular endothelial growth factor receptor (VEGFR) inhibitors indicates that the inclusion of interactions with the juxtamemebrane domain better reflects the efficacy of these drugs in renal cell carcinoma. PDF Metabolism: TAp63 tips the energy balance? p736 | doi:10.1038/nrc3386 A new study characterizes metabolic roles for the tumour suppressing TAp63 isoforms of p63. PDF RNA splicing: Layered regulation p736 | doi:10.1038/nrc3388 A pathway in which alternative splicing of histone variant isoforms regulates transcription of redox metabolism genes has been shown to have a role in tumour cell invasion and might be relevant in human breast cancer. PDF TRIAL WATCH Predicting prognosis in castrationresistant prostate cancer p736 | doi:10.1038/nrc3391 Two prospective studies reported in The Lancet Oncology have shown that mRNA expression signatures from whole blood can be used to stratify patients with castration-resistant prostate cancer into high- and low-risk groups. PDF Epigenetics: Melanoma insights written in the DNA p738 | doi:10.1038/nrc3382 A new study shows that disruptions to a DNA modification in melanoma may hold diagnostic and therapeutic promise. PDF Immunotherapy: Adapt and survive p738 | doi:10.1038/nrc3387 A new mouse model of adoptive cell transfer for the treatment of melanoma indicates that dedifferentiation of melanoma cells, driven by an inflammatory response, might have a role in resistance. PDF Tumorigenesis: Pushing pancreatic cancer to take off p739 | doi:10.1038/nrc3383 Two papers published in Cancer Cell have examined the role of epidermal growth factor receptor signalling in KRAS-driven pancreatic tumorigenesis. PDF IN BRIEF Microenvironment: The effects of endotrophin in tumour progression | Nanotechnology: Tissue penetration of photodynamic therapy | Therapeutics: Drug synergies for imatinib-resistant CML | Immunotherapy: A skin test to predict melanoma vaccine efficacy PDF Cancer JOBS of the week Endowed Professorship in Cancer Therapeutics Purdue University Postdoctoral Fellow / Cancer Stem Cells the Cancer Institute of New Jersey/UMDNJ Researcher in Genomics and high throughput genotyping in cancer Palacky University Postdoctoral Positions - Cancer Research UT Southwestern Medical Center PhD students in Cell Death Signaling & Cancer Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt More Science jobs from Cancer EVENT 1st Symposium of the Cancer Research Center of Lyon 13.-15.02.13 Lyon, France More science events from
Advertisement
The New BD FACSJazz™ Cell Sorter Perfectly tuned cell sorting is now available with the new BD FACSJazz. Built on a proven, dependable platform, it may change the way you'll think of cell sorting with ease of operation, affordability, and a benchtop fit. Exceedingly capable performance whether as a soloist or part of your core lab ensemble. bdbiosciences.com/jazz
REVIEWS		Top
The NAD metabolome — a key determinant of cancer cell biology Alberto Chiarugi, Christian Dolle, Roberta Felici & Mathias Ziegler p741 | doi:10.1038/nrc3340 NAD is a vital molecule in all organisms and is a key component of both energy and signal transduction — processes that undergo crucial changes in cancer cells. NAD+-dependent signalling reactions involve the degradation of the molecule, so permanent nucleotide resynthesis through different biosynthetic pathways is crucial for incessant cancer cell proliferation. Is targeting of NAD metabolism a new therapeutic strategy for cancer treatment? Abstract | Full Text | PDF
Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases Kenneth Verstraete & Savvas N. Savvides p753 | doi:10.1038/nrc3371 Intracellular signalling cascades initiated by class III receptor tyrosine kinases (RTK-IIIs) and their cytokine ligands are implicated in a wide range of inflammatory disorders and cancers. This Review discusses recent crystal structure data of RTK-III ectodomains in complex with cognate cytokines and the insights that these provide in terms of RTK-III activation, evolution, pathology and new therapeutic approaches. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION Cancer stem cell definitions and terminology: the devil is in the details Peter Valent, Dominique Bonnet, Ruggero De Maria, Tsvee Lapidot, Mhairi Copland, Junia V. Melo, Christine Chomienne, Fumihiko Ishikawa, Jan Jacob Schuringa, Giorgio Stassi, Brian Huntly, Harald Herrmann, Jean Soulier, Alexander Roesch, Gerrit Jan Schuurhuis, Stefan Wöhrer, Michel Arock, Johannes Zuber, Sabine Cerny-Reiterer, Hans E. Johnsen, Michael Andreeff & Connie Eaves p767 | doi:10.1038/nrc3368 This article outlines some of the issues surrounding the terminology used for cancer stem cells (CSCs) and how CSCs are defined, with an aim to develop a consensus. More precise reporting of parameters used to identify CSCs is also recommended to enhance our understanding of CSC biology and to ultimately eradicate these cells in patients. Abstract | Full Text | PDF | Supplementary information
OPINION Challenges and opportunities in childhood cancer drug development Robin E. Norris & Peter C. Adamson p776 | doi:10.1038/nrc3370 Despite recent advances, the acute and long-term morbidity of current curative therapies can be substantial, and several childhood cancers still have unacceptably low cure rates. Does the development of molecularly targeted anticancer drugs offer the prospect of more effective therapy for childhood cancers? Abstract | Full Text | PDF
OPINION Phospholipase signalling networks in cancer Jong Bae Park, Chang Sup Lee, Jin-Hyeok Jang, Jaewang Ghim, Youn-Jae Kim, Sungyoung You, Daehee Hwang, Pann-Ghill Suh & Sung Ho Ryu p782 | doi:10.1038/nrc3379 Although the roles of individual phospholipases and their lipid mediators in cancer have been studied extensively, it is less clear how these enzymes interact with each other and other cellular pathways to affect cancer-associated processes. This Opinion article argues that a thorough understanding of phospholipase signalling networks is necessary to determine whether these enzymes can be targeted therapeutically. Abstract | Full Text | PDF | Supplementary information
Advertisement
SUBSCRIBE to Nature Reviews CancerTODAY and receive your own personal copy delivered directly to your door each month. PLUS you will gain full online access to the entire archive since launch. Nature Reviews Cancer is the no. 1 monthly review journal in oncology*. Ensure you have access.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2010 Journal Citation Report (Thomson Reuters, 2011)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.